Fig. 7.

TY-52156 strengthens the blood–tumor barrier in vivo. a Mice harboring experimental brain metastases from the 231-BR or the SUM190-BR received 10 mg kg⁻¹ TY-52156 or vehicle, b.i.d. by oral gavage, for 4 days. On the fourth day of treatment, mice were injected with TRD and perfused 10 min later. Brain and blood were taken at necropsy. b–e TRD pictures were taken, subsequently the same tissue slides were stained for human cytokeratin or CD31 to normalize TRD diffusion to either metastasis cellularity or blood vessel density, respectively. b,c Graphs represent metastatic clusters from 11 and eight mice for vehicle and 10 mg kg⁻¹ TY-52156, respectively. b TRD/cytokeratin intensity in 231-BR brain metastatic clusters. c TRD/CD31 intensity in 231-BR brain metastatic clusters. d,e Graphs represent metastatic clusters from five and eight mice for vehicle and 10 mg kg⁻¹ TY-52156, respectively. d TRD/cytokeratin intensity in SUM190-BR brain metastatic lesions. e TRD/CD31 intensity in SUM190-BR brain metastatic lesions. b–e One dot represents one cluster of metastases in the 231-BR model and one lesion in the SUM190-BR model. Graphs represent the median, the interquartile range (box), and the min/max values (error bars). Two-tailed Mann–Whitney statistical analysis; *P < 0.05; ****P < 0.0001